Does microbial contamination influence the success of the hematopoietic cell transplantation outcomes?

Dal, Mehmet Sinan; Tekgündüz, Emre; Çakar, Merih Kızıl; Kaya, Ali Hakan; Namdaroğu, Sinem; Batgi, Hikmetullah; Bekdemir, Filiz; Ulu, Bahar Uncu; Yiğenoğlu, Tuğçe Nur; Kılınç, Ali; İskender, Dicle; Bilge, Uğur; Koçubaba, Şerife; İskender, Gülşen; Altuntaş, Fevzi

doi:10.1016/j.transci.2016.05.001

Cited by 14 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some centers perform transplantations of bacteria-contaminated HSC products but patients are supported by antibiotic therapy [1,2,13,14,15]. In others, contaminated products are tested for bacterial presence also after thawing, which facilitates the patient's follow-up.…”

Section: Discussionmentioning

confidence: 99%

Microbial contamination risk in hematopoietic stem cell products: retrospective analysis of 1996–2016 data

Antoniewicz‐Papis

Lachert

Rosiek

et al. 2020

Acta Haematologica Polonica

View full text Add to dashboard Cite

Quality assurance and safety of hematopoietic stem cells (HSC) with special emphasis on bacterial and fungal contamination is the prerequisite for any transplantation procedure. The aim was to determine the incidence rate of such contamination during processing of transplantation material with regard to HSC source: peripheral blood stem cell (PBSC), bone marrow (BM), or cord blood (CB). Analysis involved autologous and allogenic products dedicated for patients and comprised in all 4135 donations, including 112 BM (2.70%), 3787 PBSC (91.60%), and 236 CB (5.70%) processed in cell bank over the period 1996–2016. Aerobic and anaerobic contamination was determined.Analysis of the 20-year data revealed 42 contaminated products: 25 PBSC (0.66% of tested units) and 17 CB (7.20% of tested units). No microbial contamination of BM products was detected. Overall percentage of contaminated products was 1.01%, mostly with Staphylococcus epidermidis (61.36%). Bacterial contamination rate at cell bank is relatively low and processing in a closed system does not seem as crucial as might be expected. This is particularly true for BM components. Equally important are evaluation of donor’s medical status and condition of the puncture site for collection of source material. Implementation of appropriate sample collection procedures should help minimize the risk of false-positive results due to environmental contamination.

show abstract

Section: Discussionmentioning

confidence: 99%

Microbial contamination risk in hematopoietic stem cell products: retrospective analysis of 1996–2016 data

Antoniewicz‐Papis

Lachert

Rosiek

et al. 2020

Acta Haematologica Polonica

View full text Add to dashboard Cite

show abstract

“…In this study, we have successfully developed an in‐house protocol for antibiotic neutralization in CB sterility testing samples at Canadian Blood Services' Cord Blood Bank. Although serious septic cases in transplant patients are rare because of patient antibiotic treatment, there have been reports of transplantation reactions, ranging from nonserious to fatal, due to contaminated hematopoietic stem cell products . Importantly, isolation of antibiotic‐resistant bacteria from CB units, which would pose a high septic risk to transplantation patients, has been reported …”

Section: Discussionmentioning

confidence: 99%

Development of a proof of principle for universal neutralization of antibiotics in cord blood by‐products used for sterility testing

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Microbial contamination is managed with broad‐spectrum antibiotic prophylaxis . Studies demonstrate no long‐term effects on cell engraftment in these instances . Intermediate‐term toxicities with newer immunotherapies (cytokine release syndrome, neurotoxicity) are managed in conjunction with the primary clinical team along with a hematologic consult .…”

Section: Product Thaw Infusion and Adverse Events Monitoringmentioning

confidence: 99%

“…50 Studies demonstrate no long-term effects on cell engraftment in these instances. 51 Intermediate-term toxicities with newer immunotherapies (cytokine release syndrome, neurotoxicity) are managed in conjunction with the primary clinical team along with a hematologic consult. 52,53 It is also important to train emergency physicians and intensive care unit teams to manage unanticipated and severe adverse events.…”

Section: Product Thaw Infusion and Adverse Events Monitoringmentioning

confidence: 99%

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

et al. 2019

View full text Add to dashboard Cite

show abstract

Does microbial contamination influence the success of the hematopoietic cell transplantation outcomes?

Cited by 14 publications

References 13 publications

Microbial contamination risk in hematopoietic stem cell products: retrospective analysis of 1996–2016 data

Microbial contamination risk in hematopoietic stem cell products: retrospective analysis of 1996–2016 data

Development of a proof of principle for universal neutralization of antibiotics in cord blood by‐products used for sterility testing

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

Contact Info

Product

Resources

About